Skip to main content
Move the World.
antisense oligonucleotide therapy

Lead Image © HQUALITY / Adobe Stock

Researchers at the University of Pennsylvania have reversed a genetic form of blindness in a patient using just one course of antisense oligonucleotide therapy, Clinical OMICS reports.

The therapy, which takes aim at mutant RNA, was injected into the patient's eyes a year ago, in a trial treating Leber congenital amaurosis (LCA). LCA predominantly affects the retina, leaving people with severely impaired vision from birth, according to the NIH.

The trial, held at the Scheie Eye Institute at Penn's Perelman School of Medicine, focused on using antisense oligonucleotide therapy to treat LCA patients with one of the disease's most common mutations. 

Augmenting RNA

Antisense oligonucleotide therapy works by altering the RNA, the messenger that carries instructions from your DNA to crank out proteins.

An article in Nature Reviews Neurology describes antisense oligonucleotides as "short, synthetic, single-strand" molecules, which can alter RNA to cause protein creation to be reduced, enhanced, or modified.

In the Penn study, the targeted protein was created by the mutated LCA gene. 

The team, led by professors Artur V. Cideciyan and Samuel G. Jacobson, injected an antisense oligonucleotide (called sepofarsen) into the eyes of 11 patients. 

In a previous study, according to Clinical OMICS, the team had shown that administering the therapy every three months increased the amount of the proper protein levels in 10 patient's eyes, improving their sight in daytime conditions.

But it's the experience of the eleventh patient that's the subject of their new paper, published in Nature Medicine

One Shot 

That eleventh patient chose to receive only one course of sepofarsen and turned down the additional doses.

The patient had suffered from poor visual acuity, reduced fields of view, and zero night vision, Clinical OMICS reports, but after one shot, the patient showed remarkable improvement over the course of the next 15 months — similar to people who got multiple, regular injections.

"Our results set a new standard of what biological improvements are possible with antisense oligonucleotide therapy in LCA caused by CEP290 mutations," Cideciyan told Clinical OMICS.

Interestingly, the effects of the shot had a delayed onset; while improvement was shown after one month, the gains peaked around three months later, the authors write. That slow uptake was unexpected, and it may hold insights into treating other diseases that impact retinal cell's cilia (aka, those little vibrating hairs), the physical cause of LCA. 

Antisense oligonucleotide therapy may be effective because the tiny molecules can slip inside the cell's nucleus, but don't get swept out too quickly, so they can stick around until the job's done.

The therapy's success, and the unexpected success of a single injection, is inspiring other clinical trials. 

"This work represents a really exciting direction for RNA antisense therapy."

Samuel G. Jacobson

"There are now, at least in the eye field, a series of clinical trials using antisense oligonucleotides for different genetic defects spawned by the success of the work in CEP290-associated LCA from Drs. Cideciyan and Jacobson," Joan O'Brien, chair of ophthalmology and director of the Scheie Eye Institute, told Clinical OMICS. 

Multiple antisense therapies have already been approved by the FDA, particularly for neurological conditions, and have shown success in treating spinal muscular atrophy and Duchenne muscular dystrophy. Per Neurology Genetics, antisense oligonucleotide therapy trials are currently being developed for Huntington's, Parkinson's, and Alzheimer's disease, among others.

And now add genetic blindness to that list.

"This work represents a really exciting direction for RNA antisense therapy. It's been 30 years since there were new drugs using RNA antisense oligonucleotides," Jacobson told Clinical OMICS, "even though everybody realized that there was great promise for these treatments."

We'd love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at [email protected]

Up Next

Superhuman
The Experimental Procedure That Can Reverse Blindness
The Experimental Procedure That Can Reverse Blindness
Superhuman
The Experimental Procedure That Can Reverse Blindness
Doctors told Vanna she was permanently blind. But thanks to an experimental procedure, she can see.
By Mike Riggs

Doctors told Vanna she was permanently blind. But thanks to an experimental procedure, she can see.

Superhuman
Reversing Blindness
Reversing Blindness
Watch Now
Superhuman
Reversing Blindness
Vanna was legally blind. Now she can see. Hear her inspiring story and meet the amazing doctors who gave her back her sight.
Watch Now

Vanna started to notice a change in her vision. Six months later, she was legally blind. But Vanna never lost hope, and enrolled in an experimental clinical trial. Her doctors injected stem cells from her hip into her optic nerve. Afterwards, she started to regain her vision. Amazingly, Vanna can now see. This is the story of reversing blindness.

Medical Innovation
Scientists 3D Print a Heart Pump That Can Beat on Its Own
Heart Pump
Medical Innovation
Scientists 3D Print a Heart Pump That Can Beat on Its Own
Scientists 3D print a heart pump capable of beating on its own — and the organoid could have a big impact on heart research.

Scientists 3D print a heart pump capable of beating on its own — and the organoid could have a big impact on heart research.

Coronavirus
Can Old Vaccines Be New Weapons Against COVID-19?
repurposed vaccine
Coronavirus
Can Old Vaccines Be New Weapons Against COVID-19?
Well-established vaccines using weakened pathogens provide general immune benefits. Now researchers are proposing them to help fight COVID-19.

Well-established vaccines using weakened pathogens provide general immune benefits. Now researchers are proposing them to help fight COVID-19.

Dope Science
The Case for Love-Enhancing Drugs
interview with Brian D. Earp
Dope Science
The Case for Love-Enhancing Drugs
Drugs don’t just affect the user; they shape relationships too. And a pair of bioethicists thinks we should consider them for relationship enhancement.

Drugs don’t just affect the user; they shape relationships too. And a pair of bioethicists thinks we should consider them for relationship enhancement.

Superhuman
Reprogramming Your Immune System to Fight Cancer
Reprogramming Your Immune System to Fight Cancer
Watch Now
Superhuman
Reprogramming Your Immune System to Fight Cancer
Your T cells already know how to kill cancer. These doctors can train them to hunt it down.
Watch Now

Josh Feldman was on his honeymoon when he felt a lump on his neck. Returning home after the best month of his life, his doctor gave him the news: non-Hodgkin's lymphoma. There was no cure, and it was about to get much worse. After multiple rounds of chemotherapy failed to stop his tumors from growing, Josh went to see Dr. John Timmerman, an oncologist at UCLA who is trying something different, known as immunotherapy. This...

The New Space Race
Preparing the First Space Colonizers for Life Off of Planet Earth
Preparing the First Space Colonizers for Life Off of Planet Earth
The New Space Race
Preparing the First Space Colonizers for Life Off of Planet Earth
It’s only a matter of time until the average person can explore space. But, will the average person be ready?
By Mike Riggs

It’s only a matter of time until the average person can explore space. But, will the average person be ready?

Superhuman
Meet the Mom Curing Her Daughter's Incurable Disease
Meet the Mom Curing Her Daughter's Incurable Disease
Superhuman
Meet the Mom Curing Her Daughter's Incurable Disease
Karen Aiach isn't a doctor and has never worked in medicine. But when doctors said her daughter wouldn't live past...
By Mike Riggs

Karen Aiach isn't a doctor and has never worked in medicine. But when doctors said her daughter wouldn't live past adolescence, she knew she had to get to work.